PhaseBio Pharmaceuticals Financials

PhaseBio Pharmaceuticals Stock Summary

PhaseBio Pharmaceuticals competes with Processa Pharmaceuticals. PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Phasebio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 60 people.

PhaseBio Pharmaceuticals Key Financial Ratios

PhaseBio Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from PhaseBio Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of PhaseBio Pharmaceuticals over time and compare it to other companies across industries.

PhaseBio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining PhaseBio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare PhaseBio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PhaseBio Pharmaceuticals competition to find correlations between indicators driving PhaseBio Pharmaceuticals's intrinsic value. More Info.PhaseBio Pharmaceuticals is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PhaseBio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

PhaseBio Pharmaceuticals Market Pulse

Along with financial statement analysis, the daily predictive indicators of PhaseBio Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PhaseBio Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of PhaseBio Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing PhaseBio Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PhaseBio Pharmaceuticals's daily price indicators and compare them against related drivers.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.